Novavax Inc (NVAX) Stock Price & Analysis
Novavax Inc (NVAX) rose 0.58% to USD 8.67 as of June 9, 2026 at 23:46 UTC, according to Nexqual real-time market data.
NVAX last closed at USD 8.62; the session ranged USD 8.35–8.86 on volume of 4,510,559 shares. Market capitalization is $1.43B, with a 52-week range of USD 6.13–11.97 (NMS). Source: Nexqual, June 9, 2026 at 23:46 UTC.
Key Statistics (as of June 9, 2026 at 23:46 UTC)
| Price | USD 8.67 |
|---|---|
| Change | ▲ 0.58% (up) |
| Previous Close | USD 8.62 |
| Open | USD 8.75 |
| Day Range | USD 8.35 – 8.86 |
| 52-Week Range | USD 6.13 – 11.97 |
| Volume | 4,510,559 shares |
| Market Cap | $1.43B |
| Exchange | NMS |
Technical Analysis (NVAX)
Nexqual's technical model rates NVAX "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 23:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.49 (neutral) |
| vs SMA50 | Below (USD 8.9) |
| MACD | 0.12 (positive) |
Analyst Ratings (NVAX)
Wall Street analysts rate NVAX "Buy" based on 9 analysts, with a mean price target of USD 14.11 (range USD 7–25), per Nexqual as of June 9, 2026 at 23:46 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 14.11 |
| High Target | USD 25 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 5 / 1 / 3 |
Earnings (NVAX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.42 |
| Revenue Estimate | $58.14M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.06 vs est -0.24 ▲ beat |
| 2025-12-31 | USD 0.11 vs est -0.49 ▲ beat |
| 2025-09-30 | USD -1.25 vs est -1.17 ▼ miss |
| 2025-06-30 | USD 0.62 vs est -0.08 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:46 UTC.
Financials & Fundamentals (NVAX)
| Total Revenue | $596.34M |
|---|---|
| Revenue Growth (YoY) | -79.10% |
| Gross Margin | +27.49% |
| Operating Margin | -7.19% |
| Profit Margin | -14.73% |
| Current Ratio | 2.48 |
| Total Cash | $790.33M |
| Total Debt | $295.06M |
| Free Cash Flow | $58.57M |
Source: Nexqual, June 9, 2026 at 23:46 UTC.
Financial Health Score (NVAX)
Nexqual rates Novavax Inc's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:46 UTC.
| Growth | Strong — Revenue +65% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 27%, operating -7% |
| Balance Sheet | Mixed — $790M cash vs $295M debt, net cash position |
| Cash Flow | Solid — FCF $59M, 5% margin |
| Efficiency | Mixed — No data |
Ownership (NVAX)
| Insider Ownership | +5.01% |
|---|---|
| Institutional Ownership | +69.55% |
| Shares Outstanding | 164.44M |
| Float | 141.47M |
| Short % of Float | +27.71% |
Source: Nexqual, June 9, 2026 at 23:46 UTC.
Leadership (NVAX)
Novavax Inc is led by John Charles Jacobs (age 58), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:46 UTC.
| President, CEO & Director | John Charles Jacobs (age 58) |
|---|---|
| Executive VP, CFO & Treasurer | James Patrick Kelly C.F.A. (age 59) |
| Executive VP & Chief Strategy Officer | Elaine O'Hara (age 57) |
| Executive VP & COO | Richard P. Crowley (age 68) |
| Vice President of Investor Relations | Luis Sanay C.F.A. |
Major Backers & Investors (NVAX)
Notable institutional backers of Novavax Inc include Shah Capital Management, Shaw D.E. & Co., Inc., Sanofi, according to Nexqual as of June 9, 2026 at 23:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Shah Capital Management | 9.03% |
| Shaw D.E. & Co., Inc. | 4.69% |
| Sanofi | 4.18% |
| Bank of America Corporation | 4.04% |
| UBS Group AG | 2.72% |
| Fidelity | 0.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.47% |
| BlackRock | 11.27% |
| State Street | 8.6% |
| Geode Capital | 2.37% |
Source: Nexqual, June 9, 2026 at 23:46 UTC.
From Novavax Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
- The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
- It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRNA | Moderna, Inc. | USD 47.73 | ▲ 0.61% |
| INO | Inovio Pharmaceuticals, Inc. | USD 1.1 | ▲ 2.8% |
| BNTX | BioNTech SE | USD 86.5 | ▼ 1.79% |
| VXRT | Vaxart, Inc. | USD 0.58 | ▼ 6.45% |
| AZN | AstraZeneca PLC | USD 183.43 | ▼ 1.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:46 UTC. This page is informational and not investment advice.